Cerebral infarction

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

Retrieved on: 
Thursday, April 4, 2024
Brain, Ambient occlusion, AIS, Cerebral infarction, Patient, Stroke, Sale, Thrombolysis, Reperfusion, FDA, Interventional Neuroradiology, Medical device

RapidPulse is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.

Key Points: 
  • RapidPulse is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.
  • In this study, 40 patients were enrolled in the RapidPulse arm and treated using an 0.071-inch catheter.
  • The investigators used commercially available aspiration catheters ranging in size from 0.070 to 0.072 to treat the control arm patients with standard aspiration pumps.
  • Dr. Serdar Geyik from Istanbul's Aydin University commented, “This is an exciting improvement for the treatment of ischemic stroke due to large vessel occlusion.

Professor J Mocco to Join Protembis’ Board of Directors

Retrieved on: 
Tuesday, August 29, 2023
Cardiology, Biotechnology, Health, General Health, Venture Capital, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, Society, Interventional neuroradiology, Senior, Journal of NeuroInterventional Surgery, Clinical trial, Neurology, Brain, Mount Sinai, Aortic stenosis, Professor, Journal, Publication, Patient, FAHA, Physician, Icahn School of Medicine at Mount Sinai, Cerebral infarction, Femoral artery, TAVR, Diagnosis, Neurosurgery, IDE, FDA, Ricky Kalmon, Safety, Pharmaceutical industry, Medical device, Stroke

Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the appointment of Professor J Mocco MD, MS, FAANS, FAHA of Icahn School of Medicine at Mount Sinai, NY, USA as an independent member of their Board of Directors.

Key Points: 
  • Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the appointment of Professor J Mocco MD, MS, FAANS, FAHA of Icahn School of Medicine at Mount Sinai, NY, USA as an independent member of their Board of Directors.
  • Over his distinguished medical career spanning more than 20 years, he has authorship credits on over 600 publications.
  • In his new role on the Board of Protembis, Professor Mocco will offer insights into the strategic direction of the company with his deep knowledge and clinical insights of endovascular stroke diagnosis and management.
  • “I have been impressed by the Protembis team’s achievements in developing an elegant system to mitigate cerebral infarction risk during Transcatheter Aortic Valve Replacement” says Professor Mocco.

Heuron Participates in the Asian-Oceanian Congress of Neuroradiology (AOCNR) 2023

Retrieved on: 
Thursday, August 17, 2023
Health, Technology, Neurology, Health Technology, Software, Radiology, Artificial Intelligence, CE, Classification, Stroke, Neurodegenerative disease, PET, Multimedia, Research, Sympathetic nervous system, Certification, Ambient occlusion, Congress, MRI, Dementia, Parkinson's disease, Patient, Intraparenchymal hemorrhage, Cerebral infarction, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Alzheimer's disease, Food, Medical device, Medical imaging, Neuroradiology

Heuron , a medical artificial intelligence (AI) solution company (Donghoon Shin, CEO), announced its participation in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which will be held in Singapore from August 18th.

Key Points: 
  • Heuron , a medical artificial intelligence (AI) solution company (Donghoon Shin, CEO), announced its participation in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which will be held in Singapore from August 18th.
  • View the full release here: https://www.businesswire.com/news/home/20230816768554/en/
    Heuron, a medical AI solution company, participates in the Asian-Oceanian Congress of Neuroradiology 2023 (AOCNR 2023), which is held in Singapore from August 18th.
  • Heuron showcases its neurodegenerative disease AI solution such as Heuron AgingCare Suite, and its integrated stroke solution, Heuron StroCare Suite, to engage in global collaborations and partnerships.
  • Heuron AgingCare Suite™ includes neurodegenerative diseases solutions for Parkinson's disease (Heuron IPD and Heuron NI), and Alzheimer's disease (Heuron AD and Heuron Brain PET).

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

Retrieved on: 
Tuesday, July 25, 2023
Food, Dyslipidemia, Myocardial infarction, Triglyceride, Cardiovascular disease, NAMS, Apolipoprotein, Patient, CETP, Physician, Risk, LDL, Cerebral infarction, ASCVD, Moyamoya disease, Safety, FESC, Pharmaceutical industry

NAARDEN, The Netherlands and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease (“CVD”) with residual elevation of low-density lipoprotein cholesterol (“LDL-C” or “LDL”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the completion of patient enrollment in the pivotal Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”) and/or established atherosclerotic cardiovascular disease (“ASCVD”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The target enrollment of 2,400 subjects was exceeded due to strong interest from patients and physicians globally. NewAmsterdam expects over 2,500 patients to be randomized following the completion of ongoing patient screening and remains on track to report topline data in the second half of 2024.

Key Points: 
  • The target enrollment of 2,400 subjects was exceeded due to strong interest from patients and physicians globally.
  • NewAmsterdam expects over 2,500 patients to be randomized following the completion of ongoing patient screening and remains on track to report topline data in the second half of 2024.
  • The mean baseline LDL-C for enrolled patients is approximately 100 mg/dL despite high intensity statin use reported by greater than 60% of patients during screening.
  • “It has become increasingly clear that lower levels of LDL-C are directly correlated with a reduced risk for major adverse cardiovascular events.

NovaSignal Donates NovaGuide™ 2 Intelligent Ultrasound to The Jacobs Institute to Advance Stroke Research

Retrieved on: 
Tuesday, February 28, 2023
Jacobs, Embolism, MD, CMO, Cerebral infarction, Risk, Brain, Research, Gates Vascular Institute, Algorithm, Patient, TCD, Jacobs Institute for Design Innovation, Jacobs School of Medicine and Biomedical Sciences, Doctor of Philosophy, United, Kaleida Health, Robotics, Vascular disease, Stroke, Medical imaging, Buffalo

A non-profit vascular medical technology innovation center, the Jacobs Institute operates at the forefront of developing the next generation of medical technology for the treatment of vascular disease.

Key Points: 
  • A non-profit vascular medical technology innovation center, the Jacobs Institute operates at the forefront of developing the next generation of medical technology for the treatment of vascular disease.
  • The robotic NovaGuide 2 Intelligent Ultrasound makes it easier for healthcare professionals to monitor patients during medical procedures.
  • “Vascular disease research continues to evolve and advance because of companies like NovaSignal,” said Adnan H. Siddiqui, MD, Ph.D., CEO/CMO of the Jacobs Institute and Director of Neurosurgical Stroke Service for Kaleida Health.
  • “We’re honored to receive this donation and to continue the important research about stroke related events following cardiac procedures.

Unstoppable Rise of Korean Medical Tourism

Retrieved on: 
Tuesday, September 20, 2022
International Medical Travel Journal, Ministry, Medicine, Medical tourism, Welfare, Immunity, Cerebral infarction, Patient, Degenerative disease, Breast cancer, Cardiology, South Korea, Hospital, Cosmetics, View, Organ transplantation, Pharmaceutical industry, Online shopping, Healthcare, Health

SEOUL, South Korea, Sept. 19, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) has revamped the official website of Medical Korea(www.medicalkorea.or.kr), featuring information related to the use of Korean medical services.

Key Points: 
  • SEOUL, South Korea, Sept. 19, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) has revamped the official website of Medical Korea( www.medicalkorea.or.kr ), featuring information related to the use of Korean medical services.
  • Korea has been awarded by the International Medical Travel Journal (IMTJ) for "Health and Medical Tourism: Destination of the Year" for two consecutive years, being globally recognized for its competitiveness in medical tourism.
  • Information on operations and treatment of medical specialties, including oncology, cardiology and organ transplantation, are available on the Medical Korea website, which has a list of clinics and hospitals designated to treat foreign patients.
  • it is striving to generate the 'Korean-wave' in the global healthcare industry by combining the strength of Korea's medical services, pharmaceutical products, medical devices and cosmetics.

Unstoppable Rise of Korean Medical Tourism

Retrieved on: 
Tuesday, September 20, 2022
International Medical Travel Journal, Ministry, Medicine, Medical tourism, Welfare, Immunity, Cerebral infarction, Patient, Degenerative disease, Breast cancer, Cardiology, South Korea, Hospital, Cosmetics, Organ transplantation, Pharmaceutical industry, Healthcare, Health

SEOUL, South Korea, Sept. 20, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) has revamped the official website of Medical Korea (www.medicalkorea.or.kr), featuring information related to the use of Korean medical services.

Key Points: 
  • SEOUL, South Korea, Sept. 20, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) has revamped the official website of Medical Korea ( www.medicalkorea.or.kr ), featuring information related to the use of Korean medical services.
  • Korea has been awarded by the International Medical Travel Journal (IMTJ) for "Health and Medical Tourism: Destination of the Year" for two consecutive years, being globally recognized for its competitiveness in medical tourism.
  • Information on operations and treatment of medical specialties, including oncology, cardiology and organ transplantation, are available on the Medical Korea website, which has a list of clinics and hospitals designated to treat foreign patients.
  • it is striving to generate the 'Korean-wave' in the global healthcare industry by combining the strength of Korea's medical services, pharmaceutical products, medical devices and cosmetics.

GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)

Retrieved on: 
Monday, September 19, 2022
II, NIHSS, Safety, Human, COVID-19, Cell biology, National Institutes of Health Stroke Scale, National, Ophthalmology, Administration, Stroke, NMDA, IND, Efficacy, MRI, Psychology, Patient, BI, IDMC, CEO, III, Odds ratio, TPA, MRS, SONIC, Neuroprotection, Connective tissue disease, MFDS, Toxicity, Pharmacology, NR2B, Thrombectomy, Reperfusion, Research, Cerebral infarction, GLOBE, Mortality, GNTP, GNT, Rankine scale, Antioxidant, Brain, Pharmaceutical industry, Vaccine, Food, Neurology

Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies.

Key Points: 
  • Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies.
  • In the prior phase II trial in China (ENIS, 237 patients), administration of nelonemdaz reduced disability primarily in moderate to severe ischemic stroke patients treated with a thrombolytic drug.
  • The ENIS-3 trial was then designed to examine the efficacy and safety of nelonemdaz in 946 patients with moderate to severe acute ischemic stroke treated with tPA within 8 hours of stroke onset.
  • In China, a phase II study of nelonemdaz (ENIS trial) has been completed in acute ischemic stroke patients receiving a thrombolytic drug within 8 hours of stroke onset (n=237).

Global Acute Ischemic Stroke Drug Pipeline Market Research 2022: Comprehensive Insights About 35+ Companies and 35+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Neurology, Stem Cells, Pharmaceutical, Managed Care, Health, Medical Devices, Genetics, Clinical Trials, Mortality, Threonine, AIS, Tenecteplase, Ministry, NDA, Technology, Human, Safety, Plasmin, Clinical trial, Tissue plasminogen activator, TPA, Glutamine, Death, Bleeding, Cerebral infarction, Half-life, Antioxidant, Stroke, Organic acid, Disability, Fibrin, Therapy, Edema, News, III, TNK, Asparagine, Acquisition, Discovery, Oxidative stress, Ministry of Health and Welfare (Taiwan), NMDA, Patient, Dietary supplement, Pharmaceutical industry, Health

This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.

Key Points: 
  • This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.
  • A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines.
  • The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e.

WIMI Hologram Academy: The application of virtual reality technology in balance function disorder after cerebral apoplexy

Retrieved on: 
Wednesday, April 27, 2022
Cloud, Statistics, Computer, Injury, Feedback, Disability, CVA, Stroke, NASDAQ, Research, Work, Rehabilitation, Science, Posture, GLOBE, Subarachnoid hemorrhage, Patient, Berg Balance Scale, Muscle, VR, WIMI, Walking, Cerebral infarction, Technology, Movement, Proprioception, Ischemia, Method, Maintenance, Falls, AI, Intracranial hemorrhage, Apoplexy, Hemiparesis, Partnership, Risk, Neurophysiology, Nature, Pharmaceutical industry, Medical imaging

Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases.Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc. (NASDAQ: WIMI) have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy.

Key Points: 
  • Typically it includes cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage and other diseases.Scientists from WIMI Hologram Academy of WIMI Hologram Cloud Inc. (NASDAQ: WIMI) have studied the application of virtual reality technology in balance function disorder after cerebral apoplexy.
  • Virtual reality technology uses a computer to simulate the real world and allows the user to experience the virtual world.
  • Virtual reality technology uses computers to synthesize 3D environment models and apply these models to create and experience virtual worlds.
  • The study indicated that by combining virtual reality rehabilitation exercises with conventional rehabilitation training, patientslimb function, neurological function, balance function, as well as their life quality can be effectively improved.